Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine.
Ponticelli
C
C
IRCCS Ospedale Maggiore, Milano, Italy.
Yussim
A
A
Cambi
V
V
Legendre
C
C
Rizzo
G
G
Salvadori
M
M
Kahn
D
D
Kashi
S H
SH
Salmela
K
K
Fricke
L
L
Garcia-Martinez
J
J
Lechler
R
R
Heemann
U
U
Monteon
F
F
Ortuño
J
J
Amenabar
J J
JJ
Arias
M
M
Nicholson
M L
ML
Sperschneider
H
H
Abendroth
D
D
Gracida
C
C
Lao
M
M
Sever
M S
MS
Lameire
N
N
Sanchez-Fructuoso
A
A
Bascì
A
A
Segoloni
G
G
Connolly
J
J
Altieri
P
P
Akoh
J
J
Prestele
H
H
Girault
D
D
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D000077552:Basiliximab; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007239:Infections / Q000209:etiology; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D001379:Azathioprine; D011241:Prednisone